Abstract
Current reports indicated that the gender origin of cells is important in all facets of experimental biology. To explore this matter using an anticancer high throughput screening platform, seven male- and seven female-derived human cell lines, six from cancer patients in each group, were exposed to 81 novel cytotoxins. In this screen, the findings revealed that 79 out of 81 of the compounds consistently inflicted higher levels of toxicity towards male derived cells, emphasizing that there is indeed a gender-related difference in cell sensitivity to these anti-neoplastic agents. This gender-related drug sensitivity and toxicity explored at the molecular and cellular level emerged from a drug discovery enterprise.
This is a preview of subscription content, log in via an institution to check access.
References
Pollitzer E. Biology: cell sex matters. Nature. 2013;500:23–4.
Schiebinger L. Gendered innovations: how gender analysis contributes to research. Created: 6/14/2013, Modified: 7/8/2013. Report of the Expert Group “Innovation through Gender” http://ec.europa.eu/research/science-society/document_library/pdf_06/gendered_innovations.pdf (accessed in April, 2014).
Zhang L, Li PP, Feng X, Barker JL, Smith SV, Rubinow DR. Sex-related differences in neuronal cell survival and signaling in rats. Neurosci Lett. 2003;337:65–8.
Deitch EA, Feketeova E, Lu Q, Zaets S, Berezina TL, Machiedo GW, et al. Resistance of the female, as opposed to the male, intestine to I/R-mediated injury is associated with increased resistance to gut-induced distant organ injury. Shock. 2008;29:78–83.
Penaloza C, Estevez B, Orlanski S, Sikorska M, Walker R, Smith C, et al. Sex of the cell dictates its response: differential gene expression and sensitivity to cell death inducing stress in male and female cells. FASEB J. 2009;23:1869–79.
Lema C, Varela-Ramirez A, Aguilera RJ. Differential nuclear staining assay for high-throughput screening to identify cytotoxic compounds. Curr Cell Biochem. 2011;1:1–14.
Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med. 1997;3:402–8.
Chen EX, Moore MJ. In: Kalant H, Grant DM, Mitchell J, editors. Principles of medical pharmacology. 7th ed. Canada: Elsevier; 2007. p. 778.
Das U, Sharma RK, Dimmock JR. 1,5-Diaryl-3 –oxo-1,4-pentadienes:a case for antineoplastics with multiple targets. Curr Med Chem. 2009;16:2001–20.
Acknowledgments
Funding for this work was provided by the NIGMS SCORE grant 1SC3GM103713-01 to R.J.A., as well as a CIHR-RPP Saskatchewan grant to J.R.D and U.D. We thank the Cytometry, Screening and Imaging Core Facility at the University of Texas at El Paso (UTEP) which was supported by a RCMI program grant 8G12MD007592 to the BBRC-UTEP from the NIMHD-NIH. E.R-E, Y.S-V and N.M.O. were supported by NIGMS RISE training grant R25 GM069621-10. N.M.O. was also supported by MARC U*STAR program grant 2T34GM008048.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Nunes, L.M., Robles-Escajeda, E., Santiago-Vazquez, Y. et al. The Gender of Cell Lines Matters When Screening for Novel Anti-Cancer Drugs. AAPS J 16, 872–874 (2014). https://doi.org/10.1208/s12248-014-9617-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-014-9617-4